Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-07
2007-08-07
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S340000, C514S341000, C514S342000, C514S343000, C546S270400, C546S271100, C546S271400, C546S272100, C546S272400, C546S274100, C546S275400, C546S279100, C546S280400, C546S284700
Reexamination Certificate
active
10770814
ABSTRACT:
Described herein are compounds that are useful as protein kinase inhibitors having the formula:wherein Z1and Z2are each independently nitrogen or CH and Ring A, TmR1, QR2, UnR3, and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
REFERENCES:
patent: 5792778 (1998-08-01), de Laszlo et al.
patent: WO 95/13067 (1995-05-01), None
patent: WO 97/05878 (1997-02-01), None
patent: WO 97/16442 (1997-05-01), None
patent: WO 99/32121 (1999-07-01), None
patent: WO 99/58523 (1999-11-01), None
patent: WO 00/26209 (2000-05-01), None
patent: WO 01/74811 (2001-10-01), None
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-6, 1996.
Rogers et al., PubMed Abstract (J Cell Biol. 157(2):219-29) Apr. 2002.
Tanaka et al., PubMed Abstract (Cell. 108(3):317-29) Feb. 2000.
Hardt et al., Glycogen Synthase Kinase -3beta: A Novel Regulator of Cardiac Hypertrophy and Development, Circulation Research, 90:1055-1063, 2002.
Aronov Alex
Cao Jingrong
Green Jeremy
Hale Michael
Maltais Francois
Pearson Daniel A.
Rao Deepak
Vertex Pharmaceuticals Incorporated
LandOfFree
Heterocyclic inhibitors of ERK2 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic inhibitors of ERK2 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic inhibitors of ERK2 and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3892782